Richter, S., Seah, J.-A., Pond, G.R., Gan, H.K., Mackenzie, M.J., Hotte, S.J., Mukherjee, S.D., Murray, N., Kollmannsberger, C., Heng, D., Haider, M.A., Halford, R., Ivy, S.P., Moore, M.J. and Sridhar, S.S. 2014. Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib. Canadian Urological Association Journal. 8, 11-12 (Dec. 2014), 398–402. DOI:https://doi.org/10.5489/cuaj.2426.